Unofficial Copy

2002 Regular Session 2lr2472 CF 2lr1953

By: Delegates Owings and Redmer

Introduced and read first time: February 6, 2002

Assigned to: Environmental Matters

A BILL ENTITLED

1	AN	ACT	concerning
	7 11 1	1101	concerning

- 2 Medical Assistance Pharmaceutical Products Accessibility and Coverage 3 Protection for Enrollees
- 4 FOR the purpose of prohibiting the Department of Health and Mental Hygiene from
- 5 implementing a formulary that is covered by prior authorization in the Medical
- 6 Assistance Program unless certain provisions are met; prohibiting the
- 7 Department from restricting coverage of a drug approved by the federal Food
- 8 and Drug Administration unless the Department has certain data; prohibiting
- 9 the Department from limiting or excluding coverage of a drug prescribed for a
- 10 medical condition of a program recipient under certain circumstances; requiring
- 11 a certain formulary covered by prior authorization to have certain provisions;
- defining a certain term; and generally relating to a formulary under the Medical
- 13 Assistance Program.
- 14 BY adding to
- 15 Article Health General
- 16 Section 15-118.1
- 17 Annotated Code of Maryland
- 18 (2000 Replacement Volume and 2001 Supplement)
- 19 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
- 20 MARYLAND, That the Laws of Maryland read as follows:
- 21 Article Health General
- 22 15-118.1.
- 23 (A) IN THIS SECTION, "FORMULARY" MEANS A LIST OF PRESCRIPTION DRUGS 24 OR DEVICES.
- 25 (B) THE DEPARTMENT MAY NOT IMPLEMENT A FORMULARY THAT IS
- 26 COVERED BY PRIOR AUTHORIZATION UNLESS:
- 27 (1) THE FORMULARY DEVELOPED BY THE DEPARTMENT IS
- 28 ESTABLISHED BY A PHARMACEUTICAL AND THERAPEUTICS COMMITTEE THAT

- 1 INCLUDES PRACTICING MARYLAND PHYSICIANS, INCLUDING SPECIALTY
- 2 PHYSICIANS, PHARMACISTS, PATIENT ADVOCATES, AND OTHERS; AND
- 3 (2) THE DECISION OF THE COMMITTEE REGARDING ANY LIMITATIONS
- 4 IMPOSED ON ANY DRUG OR ITS USE FOR A SPECIFIC INDICATION SHALL BE BASED
- 5 ON SOUND CLINICAL EVIDENCE FOUND IN LABELING, DRUG COMPENDIA, AND PEER
- 6 REVIEWED CLINICAL LITERATURE PERTAINING TO USE OF THE DRUG IN THE
- 7 RELEVANT POPULATION.
- 8 (C) THE DEPARTMENT MAY NOT RESTRICT COVERAGE OF A DRUG APPROVED
- 9 BY THE FEDERAL FOOD AND DRUG ADMINISTRATION FOR AN INDICATION UNLESS
- 10 THE DEPARTMENT HAS AT LEAST 6 MONTHS OF DATA REGARDING USE OF THE DRUG
- 11 FOR TREATING PATIENTS IN THE PROGRAM.
- 12 (D) THE DEPARTMENT MAY NOT LIMIT OR EXCLUDE COVERAGE OF A DRUG
- 13 WHEN PRESCRIBED FOR THE MEDICAL CONDITION OF A PROGRAM RECIPIENT IF THE
- 14 DRUG PREVIOUSLY HAS BEEN APPROVED BY THE DEPARTMENT FOR THE
- 15 RECIPIENT'S MEDICAL CONDITION.
- 16 (E) A FORMULARY THAT IS COVERED BY PRIOR AUTHORIZATION AND
- 17 DEVELOPED BY THE DEPARTMENT SHALL:
- 18 (1) PROVIDE FOR COVERAGE OF DRUGS IN EVERY THERAPEUTIC CLASS:
- 19 AND
- 20 (2) OFFER A CHOICE OF AT LEAST TWO PHARMACEUTICAL OR
- 21 BIOLOGICAL ENTITIES WITHOUT AN ADMINISTRATIVE PREFERENCE FOR EACH
- 22 THERAPEUTIC CLASS IN WHICH THERE ARE TWO OR MORE PHARMACEUTICAL OR
- 23 BIOLOGICAL ENTITIES APPROVED BY THE FEDERAL FOOD AND DRUG
- 24 ADMINISTRATION.
- 25 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take
- 26 effect June 1, 2002.